Biomet's net sales increased 6 percent in the company's fourth quarter, which ended May 31, despite decreased sales for spine, large joint reconstructive and dental devices.
The company's fourth quarter sales totaled $784 million, compared to nearly $740 million during the same period in 2012. Spine sales dipped from $82 million in 2012 to $67 million in 2013. However, sports, extremities and trauma sales jumped from $98 million to $159 million.
Biomet's net sales for the year end totaled $3.1 billion, up 7.6 percent from 2012's $2.8 billion in net sales.
More Articles on Devices:
Wellbe Launches ACL Reconstruction-Specific Patient Guidance System
DJO Global Launches Electric Stimulator to Combat Post-Knee Surgery Muscle Atrophy
11 Spine Devices Receive FDA 510(k) Clearance in June
Biomet's net sales for the year end totaled $3.1 billion, up 7.6 percent from 2012's $2.8 billion in net sales.
More Articles on Devices:
Wellbe Launches ACL Reconstruction-Specific Patient Guidance System
DJO Global Launches Electric Stimulator to Combat Post-Knee Surgery Muscle Atrophy
11 Spine Devices Receive FDA 510(k) Clearance in June